What common practice should be undertaken when administering alkylating agents?

When administering alkylating agents, it is essential to perform baseline renal function tests because these drugs can have renal toxic effects. Alkylating agents, such as cyclophosphamide and ifosfamide, can lead to nephrotoxicity, and monitoring renal function before treatment ensures that any potential risks can be assessed and managed. Establishing a baseline renal function allows healthcare providers to tailor dosages and take preventive measures, such as increasing hydration, to minimize renal side effects during the course of treatment.

Other practices may also be important in the overall management of patients receiving chemotherapy, but baseline renal function tests are particularly crucial due to the inherent risks that alkylating agents pose to the kidneys. Ensuring proper hydration throughout treatment is also important, but primary focus on initial renal function lays the groundwork for ongoing assessment and safety during therapy.